Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Posted by Teresa Graham on May 27th, 2026

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and three have given a strong buy rating to the company.

Several research firms have weighed in on ZLDPF. BNP Paribas Exane downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. William Blair reissued a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th.

Read Our Latest Stock Analysis on Zealand Pharma A/S

Zealand Pharma A/S Price Performance

Shares of OTCMKTS:ZLDPF opened at $50.26 on Friday. Zealand Pharma A/S has a 52-week low of $35.93 and a 52-week high of $83.12. The firm has a fifty day moving average of $46.84 and a 200 day moving average of $60.81. The firm has a market capitalization of $3.60 billion, a PE ratio of 3.73 and a beta of 0.87. The company has a debt-to-equity ratio of 0.02, a quick ratio of 23.57 and a current ratio of 23.57.

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.50. The company had revenue of $5.33 million during the quarter, compared to analyst estimates of $2.81 million. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.50%. As a group, research analysts anticipate that Zealand Pharma A/S will post 2.37 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

(Get Free Report)

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.